Engineering Promoters for Specific Antigen Expression in a Synthetic DNA Vaccine Construct

Synproics有限公司和Touchlight Genetics有限公司之间的合作将结合两个高度创新和互补的技术平台，以开发一种改进的DNA疫苗开发方法。该项目将利用Synproics的专有技术，合理设计合成启动子，以驱动细胞特异性抗原表达，并增强Touchlight Genetics独特的合成DNA疫苗盒式平台的有效性。由此产生的新技术随后将被Touchlight Genetics应用于该公司的内部DNA疫苗开发项目，并可供其他开发商获得许可。该项目预计将在英国建立一种独特的合成生物学能力，用于生产更安全、更有效的DNA药物。

The collaboration between Synpromics Ltd. and Touchlight Genetics Ltd. will combine two highly innovative and complementary technology platforms to develop an improved approach to developing DNA vaccines. The project will leverage Synpromics's proprietary technology to rationally design synthetic promoters that drive cell-specific antigen expression and that enhance the effectiveness of Touchlight Genetics’s unique synthetic DNA vaccine cassette platform. The resulting new technology will subsequently be applied by Touchlight Genetics in the company’s internal DNA vaccine develoment programs, as well as be available for licensing by other developers. The project is expected to establish a unique UK-based synthetic biology capability for the production of safer and more effective DNA-based medicines.